• Prostate Cancer Free Home Page
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • News Feed
  • DONATE
Prostate Cancer Free
  • Treatments
    • Treatment Options
    • Compare Treatments
    • – Low Risk
    • – Intermediate Risk
    • – High Risk
    • Side Effects
    • Successful Treatments
    • Get The Study & Booklet
  • Prostate Cancer
    • Prostate Cancer
    • Risk Factors
    • Symptoms
    • The Prostate
    • Tests and Diagnosis
    • PSA
    • Gleason Score
    • Stages
    • Risk Groups
  • Patients
    • Top Ten Steps Prostate Cancer
    • Get the Study & Booklet
    • Patient Worksheet
    • Diet & Lifestyle
    • Glossary & Terms
    • Prostate Cancer News
    • Videos
  • The Foundation
    • About Us
      • Terms of Use
      • Privacy Policy
    • Get the Study & Booklet
    • Study Group
    • Internship Opportunities
    • Sponsors & Donors
    • Donate
  • Get The Study
Select Page

PCa Commentary #173 – MANAGING BIOCHEMICAL FAILURE AFTER RADIATION THERAPY — The Importance of Considering Both PSA and PSA Doubling Time.

by Dr. Ed Weber | Feb 14, 2023 | PCa Commentary

  The set-point for biochemical failure was standardized in 2006 based on a consensus conference of experts in Phoenix, Arizona. The value agreed upon was “PSA + 2 ng/mL above the post-radiation PSA nadir  — hence the “Phoenix Definition.” (Roach et...

PCa Commentary #172 – METASTASES DIRECTED THERAPY (MDT): Can Concomitant Hormone Suppression Be Avoided?

by Dr. Ed Weber | Dec 28, 2022 | PCa Commentary

Metastases Directed Therapy refers to targeted radiation, i.e., such as CyberKnife, directed at a few metastatic lesions, (osseous or nodal), usually 3 – 5, for the purpose of controlling all imageable disease, delaying cancer progression and, if not accompanied...

PCa Commentary #171 – Nonmetastatic Castration-Resistant Prostate Cancer: The “Ides” of Androgen Receptor Inhibition – Enzalutamide, Apalutamide and Darolutamide.

by Dr. Ed Weber | Nov 8, 2022 | PCa Commentary

Nonmetastatic castration-resistant prostate cancer (nmCRPC) is a transient, heterogeneous state that progresses to metastatic disease. nmCRPC is defined as a rising PSA after primary therapy in association with a castrate level of testosterone (<50 ng/mL) while...

PCa Commentary #170 – ACTIVE SURVEILLANCE (AS) for Men with Favorable-Intermediate Risk (F-IR) Prostate Cancer: Patient Selection and the Role of MRI Monitoring.

by Dr. Ed Weber | Oct 25, 2022 | PCa Commentary

The key to optimal outcomes in active surveillance is careful patient selection and monitoring of participants during AS. MRI guided biopsy at initial diagnosis: Lee et al., Korean J Radiol. 2021 Jul, argue that in men in whom there is a clinical suspicion of prostate...

PCa Commentary #169 – ANDROGEN DEPRIVATION THERAPY (ADT) and Radiotherapy: Basic Mechanisms and New Developments.

by Dr. Ed Weber | Sep 21, 2022 | PCa Commentary

Any man diagnosed with prostate cancer is likely aware that lowering testosterone (T) levels achieves control of the cancer at various stages of the disease. Question: What is the underlying biology and function of that therapeutic maneuver (androgen deprivation...
« Older Entries
Prostate Cancer Free Foundation
Prostate Cancer Free Foundation 10016 Edmonds Way Ste C #153 Edmonds, WA 98020, USA [email protected]

Prostate Cancer Treatments

  • Treatment Options
  • Comparing Treatments
    • Low
    • Intermediate
    • High
  • Side Effects
  • Successful Treatments
  • Get the Study & Booklet

Prostate Cancer

  • Prostate Cancer
  • Risk Factors
  • Symptoms
  • The Prostate
  • Tests and Diagnosis
  • PSA
  • Gleason Score
  • Stages
  • Risk Groups

Patients

  • Top Ten Steps Prostate Cancer
  • Get The Study & Booklet
  • Patient Worksheet
  • Diet & Lifestyle
  • Glossary & Terms
  • Commentary & News
  • Videos
Copyright 2021 Prostate Cancer Free Foundation